Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03480854 · ClinicalTrials.gov registry record · NA
The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 694
- Enrollment target
NCT03480854: Completed NA study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT03480854 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 694 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03480854, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 694 participants
- Enrollment target
Study Summary
To establish the first systems level continuous quality improvement (CQI) collaborative for multiple sclerosis (MS) in the United States, to conduct benchmarking analyses and assessments of geographic variation in MS care quality and value, and study the effect of CQI interventions on improvement of selected performance (quality) indicators.
Primary Outcome
The percentage of eligible MS patients on disease modifying therapy (DMT access), which is operationally defined as the total number of eligible patients on DMT/the total number of patients seen per quarter at a participating center for whom DMT is an appropriate treatment option.
Interventions
- OTHER Quality Improvement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 694 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2020-12-31 |
| Phase | NA |
What the finished NCT03480854 record still lists
NCT03480854 is an interventional study that assigns participants to a tested intervention. The registered 694 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 1 intervention - of which Quality Improvement is the first listed.
NCT03480854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03480854 about?
NCT03480854 is a clinical study titled "The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative". To establish the first systems level continuous quality improvement (CQI) collaborative for multiple sclerosis (MS) in the United States, to conduct benchmarking analyses and assessments of geographic variation in MS care quality and value, and study the effect of CQI interventions on improvement of...
What is the current status of trial NCT03480854?
This trial is currently completed. It is a NA study. The enrollment target is 694 participants. The study started on 2017-07-01. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03480854?
The interventions under investigation include: Quality Improvement (OTHER).
Who is sponsoring clinical trial NCT03480854?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03480854's enrollment target sits among peer trials
694 151st of 2000 higher than 1,850 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05417594 · 695 participants · Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- NCT06801834 · 695 participants · Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI